72 Participants Needed

Deferiprone Therapy for Heart Attack

(MIRON-DFP Trial)

KP
CS
CR
Overseen ByClinical Research Coordinator
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Rohan Dharmakumar
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing Deferiprone, a medication that removes excess iron, in patients with bleeding in the heart muscle. The goal is to see if it can reduce heart damage by getting rid of extra iron. Deferiprone is effective in reducing cardiac iron load and improving cardiac function.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are using investigational drugs or devices, you must stop them 30 days before joining the trial.

What makes the drug Deferiprone unique for treating heart attacks?

Deferiprone is unique for heart attack treatment because it is primarily known as an iron chelator used for conditions like thalassemia, and its application in heart attacks is novel, potentially offering a different mechanism of action compared to standard treatments like thrombolytics or ACE inhibitors.12345

What data supports the effectiveness of the drug Deferiprone for heart attack?

Deferiprone has been shown to be effective in reducing cardiac iron load and improving heart function in patients with thalassemia, which suggests it may offer heart protection. In studies, patients treated with Deferiprone had fewer heart-related events compared to those on another treatment, indicating its potential for heart health benefits.678910

Who Is on the Research Team?

RD

Rohan Dharmakumar, PhD

Principal Investigator

Krannert Cardiovascular Research Center

KP

Keyur Vora, MD MS

Principal Investigator

Krannert Cardiovascular Research Center

Are You a Good Fit for This Trial?

This trial is for adults who've recently had a specific type of heart attack (anterior wall STEMI) and are about to have a procedure to open their blocked arteries. They must not have had previous heart attacks or procedures, severe kidney issues, known allergies to MRI contrast agents, or be pregnant. Their body weight should be under 309 lbs., and they can't have certain blood disorders or liver problems.

Inclusion Criteria

I had a specific type of heart attack affecting the front wall of my heart, confirmed by symptoms, ECG changes, and high heart markers.

Exclusion Criteria

Any clinically significant abnormality identified prior to randomization that in the judgment of the Sponsor-Investigator or Delegate would preclude safe completion of the study or confound the anticipated benefit of LIPOMED
My body weight is over 309 lbs.
Absolute neutrophil count of ANC < 1.0 x 109 /L
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Deferiprone or placebo to assess its efficacy in reducing free iron in the hemorrhagic zone of myocardial infarction

6 months

Follow-up

Participants are monitored for safety, tolerability, and treatment effects, including clinical outcomes and side effects

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Deferiprone
  • Placebo
Trial Overview The study tests if Deferiprone tablets can reduce iron in the damaged area of the heart after a hemorrhagic myocardial infarction. Patients will either receive Deferiprone or a placebo randomly, alongside standard care including an MRI scan to guide treatment.
How Is the Trial Designed?
4Treatment groups
Active Control
Placebo Group
Group I: Hemorrhagic Myocardial Infarction - DeferiproneActive Control1 Intervention
Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
Group II: Non-hemorrhagic Myocardial Infarction - DeferiproneActive Control1 Intervention
Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
Group III: Hemorrhagic Myocardial Infarction - PlaceboPlacebo Group1 Intervention
Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
Group IV: Non-hemorrhagic Myocardial Infarction - PlaceboPlacebo Group1 Intervention
Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage

Deferiprone is already approved in European Union, United States, Canada for the following indications:

๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Ferriprox for:
  • Iron overload in thalassaemia major
๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Ferriprox for:
  • Transfusional iron overload in patients with thalassemia syndromes
๐Ÿ‡จ๐Ÿ‡ฆ
Approved in Canada as Ferriprox for:
  • Iron overload in thalassemia syndromes

Find a Clinic Near You

Who Is Running the Clinical Trial?

Rohan Dharmakumar

Lead Sponsor

Trials
10
Recruited
120,000+

Cardio-theranostics LLC

Collaborator

Trials
1
Recruited
70+

Lipomed AG

Collaborator

Trials
1
Recruited
70+

Published Research Related to This Trial

Deferiprone appears to be more effective than deferoxamine in protecting the heart from iron overload, as indicated by better myocardial imaging results and a lower risk of developing or worsening cardiac disease in patients on long-term treatment.
Combining deferiprone with deferoxamine may enhance iron excretion and reduce the time needed to treat severe iron overload and reverse heart disease, although these findings need further validation through randomized controlled trials.
Deferiprone: New insight.Piga, A., Roggero, S., Vinciguerra, T., et al.[2018]
Deferiprone is an effective oral iron chelator that can match or exceed the efficacy of deferoxamine in removing excess iron, particularly improving myocardial siderosis in patients with thalassemia major.
While deferiprone can cause serious side effects like agranulocytosis in about 1% of patients, it is generally well-tolerated and can be combined with deferoxamine for better management of severe iron overload, especially in patients who struggle with standard treatments.
Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.Galanello, R.[2023]
In a study of thalassemia major patients, those treated with deferiprone showed no cardiac events during therapy or for at least 18 months after, while 52 cardiac events occurred in patients treated only with deferoxamine (DFO).
Deferiprone therapy was associated with significantly greater cardiac protection compared to DFO, suggesting it may be a safer option for preventing cardiac disease in thalassemia patients.
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.Borgna-Pignatti, C., Cappellini, MD., De Stefano, P., et al.[2021]

Citations

Deferiprone: New insight. [2018]
Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. [2023]
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. [2021]
Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. [2018]
Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. [2021]
Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. [2016]
Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis. [2014]
Defibrase, a purified fibrinolytic protease from snake venom in acute myocardial infarction. [2017]
Ischemic cardiovascular complications concurrent with administration of captopril. A clinical note. [2019]
[Coronary thrombolysis with defibrase]. [2014]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity